Bibliography
- ROBINS SJ, COLLINS D, WITTES JT et al.: Relation of Gemfibrozil Treatment and Lipid Levels with Major Coronary Events. VA-HIT: A Randomized Controlled Trial JAMA (2001) 285:1585–1591.
- RUBINS HB, ROBINS SJ, COLLINS D et al.: Distribution of lipids in 8,500 men with coronary artery disease. Am. j. Cardiol. (1995) 75:1196–1201.
- GENEST J, Jr., MCNAMARA JR, ORDOVAS JM et al.: Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary heart disease. I Am. Coll. Cardiol. (1992) 19:792–802.
- BODEN WE: High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the veterans affairs high-density lipoprotein intervention trial. Am. J. Cardiol. (2000) 86\(Suppl. 1):19–22.
- FRICK MH, ELO O, HAAPA K et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl. I Med. (1987) 317:1237–1245.
- MANNINEN V, ELO O, FRICK H et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA (1988) 260:641–651.
- RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl. j. Med. (1999) 341:410–418.
- FRUCHART J-C, STAELS B, DURIEZ P, STAELS B: The role of fibric acids in atherosclerosis. Corr. Atheroscler. Rep. (2001) 3:83–92.
- KAWAMURA M, MIYAZAKA S, TERAMOTO T et al.: Gemfibrozil metabolite inhibits in vitro low-density lipoprotein (LDL) oxidation and diminished cytotoxicity induced by oxidized LDL. Metabolism